Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Heart disease risk greater for women with a common condition they may not be aware they have - 2Fake new headlights rule steer Australian drivers astray
- 3Flourishing in Retirement: Individual Accounts of Post-Profession Satisfaction
- 4Oprah Winfrey's Favorite Wellness Destination Is A Luxurious Italian Retreat
- 5Really focusing on Succulents: Tips and Procedures
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Everything you should know before booking a trip to Spain
- Instructions to Decide the Best SUV Size for Seniors
- Turning to turkey’s tryptophan to boost mood? Not so fast
- 4 Sound blocking Earphones for Prevalent Sound and Solace
- Sarkozy says he owes France 'the truth' as he challenges conviction over alleged Libya funding
- Israeli military says it hit dozens of military facilities in Tehran
- PHOTO ESSAY: Scientists trying to unravel one of the body's biggest mysteries
- Ocean side Locations for a Family Excursion
